XLMM的个人主页 - 老虎社区

XLMM

暂无个人介绍

IP属地：未知

4关注

1粉丝

0主题

0勋章

2022-01-14

That is some analysis!

Palantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote>

2022-01-13

cant wait for their earning report...

Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>

2022-01-12

Go go go!

Novavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote>

2022-01-12

Awesome!

抱歉，原内容已删除

2022-01-12

And yes we have one of them today...South Korea! Yay!

Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>

2022-01-11

heavy discounts for the shares we love!

抱歉，原内容已删除

2022-01-07

Looks like Singapore is considering their vaccine too..

抱歉，原内容已删除

2022-01-04

Have been buying the dips!

Some Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote>

2022-01-04

Awesome! looks like several investment sites are starting to raise their price target for NVAX.

抱歉，原内容已删除

2022-01-01

‌$Novavax(NVAX)$‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021: Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine

2021-12-03

$Pfizer(PFE)$I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100909250192760","uuid":"4100909250192760","gmtCreate":1637807084742,"gmtModify":1637807084742,"name":"XLMM","pinyin":"xlmm","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.23","exceedPercentage":"80.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":694754183,"gmtCreate":1642135767949,"gmtModify":1642135767949,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"That is some analysis!","listText":"That is some analysis!","text":"That is some analysis!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694754183","repostId":"1189278661","repostType":4,"repost":{"id":"1189278661","kind":"news","pubTimestamp":1642127310,"share":"https://www.laohu8.com/m/news/1189278661?lang=zh_CN&edition=full","pubTime":"2022-01-14 10:28","market":"us","language":"en","title":"Palantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189278661","media":"Seeking Alpha","summary":"SummaryI respond to reader feedback on my most recent Palantir article.Reader feedback is divided in","content":"<p><html><head></head><body>Summary</p><p><blockquote><html><head></head><body>总结</body></html></blockquote></p><p><ul><li>I respond to reader feedback on my most recent Palantir article.</li><li>Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.</li><li>I stand by my assertion that Palantir is highly overvalued.</li></ul>My previous article on the big-data company <b>Palantir (PLTR)</b>created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company&#39;s stock is difficult, if not impossible, to justify based on the company&#39;s financials.</p><p><blockquote><ul><li>我回应读者对我最近的Palantir文章的反馈。</li><li>读者反馈分为四类：估值、公司亏损、护城河、可扩展性。</li><li>我袖手旁观我的断言，即Palantir被严重高估。</li></ul>我上一篇关于大数据公司的文章<b>帕兰蒂尔(PLTR)</b>引起了不小的轰动。有超过700条评论和大量的（负面）反馈，我认为分享我在这篇文章中收到的一些最重要的问题的想法是合适的。就披露而言，我没有Palantir的空头头寸，也不打算开设空头头寸。我只是认为，根据公司的财务状况，即使不是不可能，也很难证明公司的股票是合理的。</blockquote></p><p><b>My $5 Price Target For Palantir</b></p><p><blockquote><b>我对Palantir的目标价为5美元</b></blockquote></p><p>In my previous article, &#34;Palantir: Fair Value Of $5,&#34; I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.</p><p><blockquote>在我之前的文章“Palantir：公允价值为5美元”中，我声称这家大数据公司从根本上被不合理地高估了。我的理由是，一家像Palantir一样经营时间长的公司应该拥有更好的财务状况，看起来比我们在第十季度报告中看到的要好得多。</blockquote></p><p>My main concern was Palantir&#39;s valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir&#39;s annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir&#39;s valuation appears indefensible.</p><p><blockquote>我主要关心的是Palantir的估值，它要求买家支付20倍的销售额。在正常和更清醒的时期，20的市盈率被认为是很高的。即使考虑到Palantir 30%+的年增长率，支付（预期）销售额的20倍仍然有点牵强，并且需要对销售增长真正实现充满信心。即便如此，Palantir的估值似乎也站不住脚。</blockquote></p><p>I&#39;d like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).</p><p><blockquote>我想借此机会谈谈我收到的一些反馈，涉及我收到最多问题的四个领域（估值、公司亏损、护城河和可扩展性）。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Many readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.</p><p><blockquote>许多读者强烈不同意我的评估。我收到的最常见的问题集中在Palantir实现显着的收入增长，并且由于这种快速增长，Palantir的市值至少应该达到100亿美元。</blockquote></p><p>This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don&#39;t deny that Palantir&#39;s revenue is rapidly increasing. According to the company&#39;s long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir&#39;s outlook was confirmed in the company&#39;s most recent quarterly earnings report, and the company expects 40% growth this year.</p><p><blockquote>这一论点忽略了一个事实，即就估值而言，收入基础的规模与销售增长率同样重要。我也不否认Palantir的收入正在迅速增长。根据公司的长期销售预测，公司的目标是30%的年增长率。Palantir的前景在该公司最新的季度财报中得到证实，该公司预计今年将增长40%。</blockquote></p><p>Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn&#39;t mean the company &#34;should be worth $10 billion.&#34; This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir&#39;s revenue growth rate of 30% should not be overlooked, it is not 100%.</p><p><blockquote>Palantir正在迅速扩张，但收入基础必须与销售增长率一起考虑才能有任何意义。如果我经营一家年销售额为100万美元的企业，并且销售额每年翻一番，这并不意味着这家公司“应该价值100亿美元”。如果不考虑美元收入基础，就无法得出这一结论。虽然Palantir 30%的收入增长率不应被忽视，但它并不是100%。</blockquote></p><p>Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir&#39;s growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.</p><p><blockquote>Palantir的市值为340亿美元，市场预计2021年收入为15.3亿美元，2022年收入为19.9亿美元。这里，隐含的销售倍数为22（2021年预计）和17（2022年预计）。Palantir的增长倍数过高，面临进一步收缩的风险。为一项业务支付大约20倍销售额的费用，即使它是完美的，也不仅仅是一种延伸；这可能是一次自杀任务。</blockquote></p><p><b>IPO And Losses</b></p><p><blockquote><b>首次公开发售及亏损</b></blockquote></p><p>In response to my previous article, I received a lot of feedback along the lines of &#34;Palantir is investing money, and this money will come back later in terms of free cash flow,&#34; or &#34;Palantir just had its IPO, and profits are not expected.&#34;</p><p><blockquote>针对我之前的文章，我收到了很多反馈，大意是“Palantir正在投资，这笔钱稍后会在自由现金流方面回来”，或者“Palantir刚刚进行了IPO，利润没有预期。”</blockquote></p><p>Both arguments, in my opinion, are flawed.</p><p><blockquote>在我看来，这两种观点都有缺陷。</blockquote></p><p>Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market&#39;s opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.</p><p><blockquote>Palantir并不是一家最近上市并正在寻找资本投资的年轻公司。Palantir自2003年开始营业，至今尚未盈利。事实上，公司内部人士已经利用今年市场的机会，在2021年大量抛售A类股票。这篇文章是任何Palantir投资者的必读之作，深入探讨了今年出现的内幕销售情况。</blockquote></p><p>In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.</p><p><blockquote>换句话说，拥有股权的内部人士正在通过向毫无戒心的散户投资者抛售股票来套现，这些散户投资者愿意为一家亏损公司支付20倍的销售额。这个故事在我一生中已经被讲过好几次了。</blockquote></p><p>Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir&#39;s losses in 2021 are &#34;only&#34; $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.</p><p><blockquote>正如我在上一篇文章中解释的那样，Palantir今年不仅亏损。在其存在的整个过程中，这家大数据公司一直在亏损，并以惊人的速度累积亏损。Palantir 2021年的亏损“仅”为3.64亿美元。到9月底亏损可能会大大低于去年，但仍然是亏损。</blockquote></p><p></p><p>And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company&#39;s balance sheet and is deducted from stockholders&#39; equity. It displays the total of a company&#39;s losses accumulated during its active period of operation. Palantir&#39;s accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman&#39;s terms, Palantir has depleted 70% of its investor capital. That&#39;s a frightening figure.</p><p><blockquote>而且，在企业估值中，利润/亏损应该和销售预测一样重要，在大多数情况下，销售预测是积极的。我认为我之前的Palantir文章中忽略了一点，那就是该公司的累计亏损为53亿美元。会计规则要求累计赤字出现在公司的资产负债表上，并从股东权益中扣除。它显示公司在其活跃运营期间累计的损失总额。Palantir的累计赤字总额为53亿美元，而实收资本总额为76亿美元。通俗地说，Palantir已经耗尽了70%的投资者资本。那是一个可怕的数字。</blockquote></p><p>Concerning the statement &#34;Palantir is investing in its growth and will recoup its investment later&#34;: Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn&#39;t some of the money invested 10 or more years ago have already returned?</p><p><blockquote>关于“Palantir正在投资于其增长，并将在稍后收回投资”的说法：Palantir已经陷入这一阶段近二十年，公司仍然没有盈利。10年或更长时间前投资的一些钱不是应该已经有回报了吗？</blockquote></p><p>The magnitude of the company&#39;s accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir&#39;s capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?</p><p><blockquote>该公司累计赤字的规模以及长达二十年的亏损累积时间令人难以置信，引发了人们对Palantir资本配置的严重担忧。如果我们去一家有20年商业亏损历史的银行，你或我有资格获得多少信贷？</blockquote></p><p><b>Moat</b></p><p><blockquote><b>护城河</b></blockquote></p><p>Questions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company&#39;s clients include numerous government agencies. The implication here appears to be that Palantir&#39;s relationship network serves as a moat.</p><p><blockquote>有人质疑为什么我认为Palantir的业务缺乏重要的护城河，尽管该公司的客户包括众多政府机构。这里的含义似乎是Palantir的关系网络充当了护城河。</blockquote></p><p>Palantir works with a number of cash-rich government agencies that use the company&#39;s technology platforms across the board. I don&#39;t deny that Palantir&#39;s platforms, or &#34;foundries,&#34; as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.</p><p><blockquote>Palantir与许多现金充裕的政府机构合作，这些机构全面使用该公司的技术平台。我不否认Palantir的平台（或该公司所称的“代工厂”）执行关键的数据管理和分析功能。Palantir最近获得了美国陆军和太空系统司令部价值数百万美元的合同。陆军合同价值超过8亿美元，而太空系统司令部合同价值4300万美元。</blockquote></p><p>That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir&#39;s &#34;relationships&#34; with the government. To be honest, this would be illegal. As a result, the notion that the company&#39;s relationships aid Palantir in the construction of a moat is false.</p><p><blockquote>话虽如此，我并不否认Palantir成功获得了合同。我的意思是Palantir必须经过竞争流程才能中标。合同的授予不是基于Palantir与政府的“关系”。老实说，这是违法的。因此，认为该公司的关系有助于Palantir建立护城河的想法是错误的。</blockquote></p><p><b>Scalability</b></p><p><blockquote><b>可扩展性</b></blockquote></p><p>Some of the comments I received focused on Palantir&#39;s ability to capitalize on the big data revolution, as well as Palantir&#39;s scalability.</p><p><blockquote>我收到的一些评论集中在Palantir利用大数据革命的能力以及Palantir的可扩展性上。</blockquote></p><p>But where is this scalability, which is frequently mentioned as a reason to buy the stock?</p><p><blockquote>但这种经常被提及作为购买股票理由的可扩展性在哪里呢？</blockquote></p><p>Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of &#34;scale.&#34;<img src=\"https://static.tigerbbs.com/64df144337f177af7f37125517af8d56\" tg-width=\"640\" tg-height=\"143\" width=\"100%\" height=\"auto\"/>The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don&#39;t see real scalability with Palantir.</p><p><blockquote>Palantir表示，它需要人员向客户介绍其代工厂的功能。就人力资源而言，需要客户试点的软件既耗时又昂贵。这是“规模”的倒数。降低边际成本的能力是可伸缩性的一个关键特征。有了足够大的客户群，边际成本可以降到零。Palantir的情况并非如此，它必须向客户提供所部署平台的复杂性或引导他们了解新功能。在我看来，Palantir更类似于一家同时销售软件产品的IT咨询公司。但我认为Palantir没有真正的可扩展性。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>Palantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir&#39;s stock remains wildly overpriced.</p><p><blockquote>Palantir不是一家盈利的公司。Palantir被严重稀释。Palantir的内部人士正在抛售。即使年收入增长30%，Palantir的股价仍然被严重高估。</blockquote></p><p>High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.</p><p><blockquote>高市盈率股票，尤其是科技行业的股票，最近开始盘整，随着投资者不太愿意为那些股价飞涨但未能达到高预期的企业支付高价，更多的下跌即将到来。</blockquote></p><p>Palantir&#39;s valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir&#39;s market price.</p><p><blockquote>Palantir的估值是一个巨大的问题，尽管这家大数据公司在一个被大肆宣传的性感行业运营，但业务基本面根本无法证明Palantir的市场价格是合理的。</blockquote></p><p><b>My Conclusion</b></p><p><blockquote><b>我的结论</b></blockquote></p><p>I&#39;m not saying Palantir doesn&#39;t have significant annual sales growth. I&#39;m not saying Palantir&#39;s products are useless to the government. What I am saying is that Palantir&#39;s loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn&#39;t deserve this kind of sales multiple.</p><p><blockquote>我并不是说Palantir的年销售额没有显着增长。我并不是说Palantir的产品对政府毫无用处。我想说的是，Palantir的亏损业务不值得20倍的销售倍数。即使盈利，也不值得这样的销售倍数。</blockquote></p><p></p><p>That&#39;s why I&#39;m sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.</p><p><blockquote>这就是为什么我坚持Palantir 5美元的目标价。5美元的目标价意味着100亿美元的市场估值和5的销售倍数，这仍然是非常慷慨的。由于业务损失的持续存在，不幸的是，市盈率在这里不适用。我相信大多数反馈都是善意的，但牛市案例仍然存在一些严重缺陷。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-14 10:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Summary</p><p><blockquote><html><head></head><body>总结</body></html></blockquote></p><p><ul><li>I respond to reader feedback on my most recent Palantir article.</li><li>Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.</li><li>I stand by my assertion that Palantir is highly overvalued.</li></ul>My previous article on the big-data company <b>Palantir (PLTR)</b>created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company&#39;s stock is difficult, if not impossible, to justify based on the company&#39;s financials.</p><p><blockquote><ul><li>我回应读者对我最近的Palantir文章的反馈。</li><li>读者反馈分为四类：估值、公司亏损、护城河、可扩展性。</li><li>我袖手旁观我的断言，即Palantir被严重高估。</li></ul>我上一篇关于大数据公司的文章<b>帕兰蒂尔(PLTR)</b>引起了不小的轰动。有超过700条评论和大量的（负面）反馈，我认为分享我在这篇文章中收到的一些最重要的问题的想法是合适的。就披露而言，我没有Palantir的空头头寸，也不打算开设空头头寸。我只是认为，根据公司的财务状况，即使不是不可能，也很难证明公司的股票是合理的。</blockquote></p><p><b>My $5 Price Target For Palantir</b></p><p><blockquote><b>我对Palantir的目标价为5美元</b></blockquote></p><p>In my previous article, &#34;Palantir: Fair Value Of $5,&#34; I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.</p><p><blockquote>在我之前的文章“Palantir：公允价值为5美元”中，我声称这家大数据公司从根本上被不合理地高估了。我的理由是，一家像Palantir一样经营时间长的公司应该拥有更好的财务状况，看起来比我们在第十季度报告中看到的要好得多。</blockquote></p><p>My main concern was Palantir&#39;s valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir&#39;s annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir&#39;s valuation appears indefensible.</p><p><blockquote>我主要关心的是Palantir的估值，它要求买家支付20倍的销售额。在正常和更清醒的时期，20的市盈率被认为是很高的。即使考虑到Palantir 30%+的年增长率，支付（预期）销售额的20倍仍然有点牵强，并且需要对销售增长真正实现充满信心。即便如此，Palantir的估值似乎也站不住脚。</blockquote></p><p>I&#39;d like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).</p><p><blockquote>我想借此机会谈谈我收到的一些反馈，涉及我收到最多问题的四个领域（估值、公司亏损、护城河和可扩展性）。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Many readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.</p><p><blockquote>许多读者强烈不同意我的评估。我收到的最常见的问题集中在Palantir实现显着的收入增长，并且由于这种快速增长，Palantir的市值至少应该达到100亿美元。</blockquote></p><p>This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don&#39;t deny that Palantir&#39;s revenue is rapidly increasing. According to the company&#39;s long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir&#39;s outlook was confirmed in the company&#39;s most recent quarterly earnings report, and the company expects 40% growth this year.</p><p><blockquote>这一论点忽略了一个事实，即就估值而言，收入基础的规模与销售增长率同样重要。我也不否认Palantir的收入正在迅速增长。根据公司的长期销售预测，公司的目标是30%的年增长率。Palantir的前景在该公司最新的季度财报中得到证实，该公司预计今年将增长40%。</blockquote></p><p>Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn&#39;t mean the company &#34;should be worth $10 billion.&#34; This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir&#39;s revenue growth rate of 30% should not be overlooked, it is not 100%.</p><p><blockquote>Palantir正在迅速扩张，但收入基础必须与销售增长率一起考虑才能有任何意义。如果我经营一家年销售额为100万美元的企业，并且销售额每年翻一番，这并不意味着这家公司“应该价值100亿美元”。如果不考虑美元收入基础，就无法得出这一结论。虽然Palantir 30%的收入增长率不应被忽视，但它并不是100%。</blockquote></p><p>Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir&#39;s growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.</p><p><blockquote>Palantir的市值为340亿美元，市场预计2021年收入为15.3亿美元，2022年收入为19.9亿美元。这里，隐含的销售倍数为22（2021年预计）和17（2022年预计）。Palantir的增长倍数过高，面临进一步收缩的风险。为一项业务支付大约20倍销售额的费用，即使它是完美的，也不仅仅是一种延伸；这可能是一次自杀任务。</blockquote></p><p><b>IPO And Losses</b></p><p><blockquote><b>首次公开发售及亏损</b></blockquote></p><p>In response to my previous article, I received a lot of feedback along the lines of &#34;Palantir is investing money, and this money will come back later in terms of free cash flow,&#34; or &#34;Palantir just had its IPO, and profits are not expected.&#34;</p><p><blockquote>针对我之前的文章，我收到了很多反馈，大意是“Palantir正在投资，这笔钱稍后会在自由现金流方面回来”，或者“Palantir刚刚进行了IPO，利润没有预期。”</blockquote></p><p>Both arguments, in my opinion, are flawed.</p><p><blockquote>在我看来，这两种观点都有缺陷。</blockquote></p><p>Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market&#39;s opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.</p><p><blockquote>Palantir并不是一家最近上市并正在寻找资本投资的年轻公司。Palantir自2003年开始营业，至今尚未盈利。事实上，公司内部人士已经利用今年市场的机会，在2021年大量抛售A类股票。这篇文章是任何Palantir投资者的必读之作，深入探讨了今年出现的内幕销售情况。</blockquote></p><p>In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.</p><p><blockquote>换句话说，拥有股权的内部人士正在通过向毫无戒心的散户投资者抛售股票来套现，这些散户投资者愿意为一家亏损公司支付20倍的销售额。这个故事在我一生中已经被讲过好几次了。</blockquote></p><p>Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir&#39;s losses in 2021 are &#34;only&#34; $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.</p><p><blockquote>正如我在上一篇文章中解释的那样，Palantir今年不仅亏损。在其存在的整个过程中，这家大数据公司一直在亏损，并以惊人的速度累积亏损。Palantir 2021年的亏损“仅”为3.64亿美元。到9月底亏损可能会大大低于去年，但仍然是亏损。</blockquote></p><p></p><p>And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company&#39;s balance sheet and is deducted from stockholders&#39; equity. It displays the total of a company&#39;s losses accumulated during its active period of operation. Palantir&#39;s accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman&#39;s terms, Palantir has depleted 70% of its investor capital. That&#39;s a frightening figure.</p><p><blockquote>而且，在企业估值中，利润/亏损应该和销售预测一样重要，在大多数情况下，销售预测是积极的。我认为我之前的Palantir文章中忽略了一点，那就是该公司的累计亏损为53亿美元。会计规则要求累计赤字出现在公司的资产负债表上，并从股东权益中扣除。它显示公司在其活跃运营期间累计的损失总额。Palantir的累计赤字总额为53亿美元，而实收资本总额为76亿美元。通俗地说，Palantir已经耗尽了70%的投资者资本。那是一个可怕的数字。</blockquote></p><p>Concerning the statement &#34;Palantir is investing in its growth and will recoup its investment later&#34;: Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn&#39;t some of the money invested 10 or more years ago have already returned?</p><p><blockquote>关于“Palantir正在投资于其增长，并将在稍后收回投资”的说法：Palantir已经陷入这一阶段近二十年，公司仍然没有盈利。10年或更长时间前投资的一些钱不是应该已经有回报了吗？</blockquote></p><p>The magnitude of the company&#39;s accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir&#39;s capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?</p><p><blockquote>该公司累计赤字的规模以及长达二十年的亏损累积时间令人难以置信，引发了人们对Palantir资本配置的严重担忧。如果我们去一家有20年商业亏损历史的银行，你或我有资格获得多少信贷？</blockquote></p><p><b>Moat</b></p><p><blockquote><b>护城河</b></blockquote></p><p>Questions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company&#39;s clients include numerous government agencies. The implication here appears to be that Palantir&#39;s relationship network serves as a moat.</p><p><blockquote>有人质疑为什么我认为Palantir的业务缺乏重要的护城河，尽管该公司的客户包括众多政府机构。这里的含义似乎是Palantir的关系网络充当了护城河。</blockquote></p><p>Palantir works with a number of cash-rich government agencies that use the company&#39;s technology platforms across the board. I don&#39;t deny that Palantir&#39;s platforms, or &#34;foundries,&#34; as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.</p><p><blockquote>Palantir与许多现金充裕的政府机构合作，这些机构全面使用该公司的技术平台。我不否认Palantir的平台（或该公司所称的“代工厂”）执行关键的数据管理和分析功能。Palantir最近获得了美国陆军和太空系统司令部价值数百万美元的合同。陆军合同价值超过8亿美元，而太空系统司令部合同价值4300万美元。</blockquote></p><p>That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir&#39;s &#34;relationships&#34; with the government. To be honest, this would be illegal. As a result, the notion that the company&#39;s relationships aid Palantir in the construction of a moat is false.</p><p><blockquote>话虽如此，我并不否认Palantir成功获得了合同。我的意思是Palantir必须经过竞争流程才能中标。合同的授予不是基于Palantir与政府的“关系”。老实说，这是违法的。因此，认为该公司的关系有助于Palantir建立护城河的想法是错误的。</blockquote></p><p><b>Scalability</b></p><p><blockquote><b>可扩展性</b></blockquote></p><p>Some of the comments I received focused on Palantir&#39;s ability to capitalize on the big data revolution, as well as Palantir&#39;s scalability.</p><p><blockquote>我收到的一些评论集中在Palantir利用大数据革命的能力以及Palantir的可扩展性上。</blockquote></p><p>But where is this scalability, which is frequently mentioned as a reason to buy the stock?</p><p><blockquote>但这种经常被提及作为购买股票理由的可扩展性在哪里呢？</blockquote></p><p>Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of &#34;scale.&#34;<img src=\"https://static.tigerbbs.com/64df144337f177af7f37125517af8d56\" tg-width=\"640\" tg-height=\"143\" width=\"100%\" height=\"auto\"/>The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don&#39;t see real scalability with Palantir.</p><p><blockquote>Palantir表示，它需要人员向客户介绍其代工厂的功能。就人力资源而言，需要客户试点的软件既耗时又昂贵。这是“规模”的倒数。降低边际成本的能力是可伸缩性的一个关键特征。有了足够大的客户群，边际成本可以降到零。Palantir的情况并非如此，它必须向客户提供所部署平台的复杂性或引导他们了解新功能。在我看来，Palantir更类似于一家同时销售软件产品的IT咨询公司。但我认为Palantir没有真正的可扩展性。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>Palantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir&#39;s stock remains wildly overpriced.</p><p><blockquote>Palantir不是一家盈利的公司。Palantir被严重稀释。Palantir的内部人士正在抛售。即使年收入增长30%，Palantir的股价仍然被严重高估。</blockquote></p><p>High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.</p><p><blockquote>高市盈率股票，尤其是科技行业的股票，最近开始盘整，随着投资者不太愿意为那些股价飞涨但未能达到高预期的企业支付高价，更多的下跌即将到来。</blockquote></p><p>Palantir&#39;s valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir&#39;s market price.</p><p><blockquote>Palantir的估值是一个巨大的问题，尽管这家大数据公司在一个被大肆宣传的性感行业运营，但业务基本面根本无法证明Palantir的市场价格是合理的。</blockquote></p><p><b>My Conclusion</b></p><p><blockquote><b>我的结论</b></blockquote></p><p>I&#39;m not saying Palantir doesn&#39;t have significant annual sales growth. I&#39;m not saying Palantir&#39;s products are useless to the government. What I am saying is that Palantir&#39;s loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn&#39;t deserve this kind of sales multiple.</p><p><blockquote>我并不是说Palantir的年销售额没有显着增长。我并不是说Palantir的产品对政府毫无用处。我想说的是，Palantir的亏损业务不值得20倍的销售倍数。即使盈利，也不值得这样的销售倍数。</blockquote></p><p></p><p>That&#39;s why I&#39;m sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.</p><p><blockquote>这就是为什么我坚持Palantir 5美元的目标价。5美元的目标价意味着100亿美元的市场估值和5的销售倍数，这仍然是非常慷慨的。由于业务损失的持续存在，不幸的是，市盈率在这里不适用。我相信大多数反馈都是善意的，但牛市案例仍然存在一些严重缺陷。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4479466-palantir-a-defense-of-my-5-price-target\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4479466-palantir-a-defense-of-my-5-price-target","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189278661","content_text":"SummaryI respond to reader feedback on my most recent Palantir article.Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.I stand by my assertion that Palantir is highly overvalued.My previous article on the big-data company Palantir (PLTR)created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company's stock is difficult, if not impossible, to justify based on the company's financials.My $5 Price Target For PalantirIn my previous article, \"Palantir: Fair Value Of $5,\" I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.My main concern was Palantir's valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir's annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir's valuation appears indefensible.I'd like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).ValuationMany readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don't deny that Palantir's revenue is rapidly increasing. According to the company's long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir's outlook was confirmed in the company's most recent quarterly earnings report, and the company expects 40% growth this year.Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn't mean the company \"should be worth $10 billion.\" This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir's revenue growth rate of 30% should not be overlooked, it is not 100%.Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir's growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.IPO And LossesIn response to my previous article, I received a lot of feedback along the lines of \"Palantir is investing money, and this money will come back later in terms of free cash flow,\" or \"Palantir just had its IPO, and profits are not expected.\"Both arguments, in my opinion, are flawed.Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market's opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir's losses in 2021 are \"only\" $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company's balance sheet and is deducted from stockholders' equity. It displays the total of a company's losses accumulated during its active period of operation. Palantir's accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman's terms, Palantir has depleted 70% of its investor capital. That's a frightening figure.Concerning the statement \"Palantir is investing in its growth and will recoup its investment later\": Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn't some of the money invested 10 or more years ago have already returned?The magnitude of the company's accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir's capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?MoatQuestions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company's clients include numerous government agencies. The implication here appears to be that Palantir's relationship network serves as a moat.Palantir works with a number of cash-rich government agencies that use the company's technology platforms across the board. I don't deny that Palantir's platforms, or \"foundries,\" as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir's \"relationships\" with the government. To be honest, this would be illegal. As a result, the notion that the company's relationships aid Palantir in the construction of a moat is false.ScalabilitySome of the comments I received focused on Palantir's ability to capitalize on the big data revolution, as well as Palantir's scalability.But where is this scalability, which is frequently mentioned as a reason to buy the stock?Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of \"scale.\"The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don't see real scalability with Palantir.RisksPalantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir's stock remains wildly overpriced.High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.Palantir's valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir's market price.My ConclusionI'm not saying Palantir doesn't have significant annual sales growth. I'm not saying Palantir's products are useless to the government. What I am saying is that Palantir's loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn't deserve this kind of sales multiple.That's why I'm sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694436535,"gmtCreate":1642070803449,"gmtModify":1642070803511,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"cant wait for their earning report...","listText":"cant wait for their earning report...","text":"cant wait for their earning report...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694436535","repostId":"1107505154","repostType":2,"repost":{"id":"1107505154","kind":"news","pubTimestamp":1642035550,"share":"https://www.laohu8.com/m/news/1107505154?lang=zh_CN&edition=full","pubTime":"2022-01-13 08:59","market":"us","language":"en","title":"Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1107505154","media":"Yahoo Finance","summary":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizat","content":"<p><html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.</p><p><blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在疫情留下自己的印记。</body></html></blockquote></p><p>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.</p><p><blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote></p><p>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.</p><p><blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote></p><p>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.</p><p><blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote></p><p>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.</p><p><blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote></p><p>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.</p><p><blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote></p><p>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.</p><p><blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote></p><p>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.</p><p><blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote></p><p>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.</p><p><blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote></p><p>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.</p><p><blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote></p><p>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.</p><p><blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote></p><p><b>Manufacturing hurdles</b></p><p><blockquote><b>制造障碍</b></blockquote></p><p>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.</p><p><blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote></p><p>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.</p><p><blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote></p><p>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.</p><p><blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote></p><p>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.</p><p><blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote></p><p>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.</p><p><blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote></p><p>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.</p><p><blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote></p><p>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.</p><p><blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote></p><p>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.</p><p><blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote></p><p>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.</p><p><blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote></p><p>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.</p><p><blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote></p><p>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;</p><p><blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote></p><p>Global vaccine market</p><p><blockquote>全球疫苗市场</blockquote></p><p>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.</p><p><blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote></p><p>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.</p><p><blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote></p><p>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.</p><p><blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote></p><p></p><p>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.</p><p><blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote></p><p>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.</p><p><blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote></p><p>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.</p><p><blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote></p><p>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.</p><p><blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote></p><p>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.</p><p><blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax CEO: 'We're Going to Make a Significant Impact on This COVID Pandemic'<blockquote>Novavax首席执行官：“我们将对这场新冠疫情产生重大影响”</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Yahoo Finance</strong><span class=\"h-time small\">2022-01-13 08:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it&#39;s making its mark on the pandemic.</p><p><blockquote><html><head></head><body>Novavax(NVAX)正在等待其COVID-19疫苗在美国获得授权，但随着目前已在全球三个主要市场获得授权，这家生物技术公司表示，它正在疫情留下自己的印记。</body></html></blockquote></p><p>&#34;We&#39;re going to make a significant impact on this Covid pandemic,&#34; CEO Stanley Erck told Yahoo Finance Tuesday.</p><p><blockquote>首席执行官斯坦利·埃尔克周二对雅虎财经表示：“我们将对这场新冠疫情产生重大影响。”</blockquote></p><p>&#34;The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,&#34; Erck said.</p><p><blockquote>埃尔克说：“初级疫苗接种——两剂疫苗接种，现在被称为三剂疫苗接种——的市场并不满意。”</blockquote></p><p>&#34;It&#39;s not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,&#34; he added.</p><p><blockquote>“这不仅仅是低收入国家，因为高收入国家需要这个。我们需要克服疫苗犹豫，”他补充道。</blockquote></p><p>If the definition for &#39;fully-vaccinated&#39; changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.</p><p><blockquote>如果Novavax和mRNA疫苗的“完全接种”定义更改为三剂，这可能意味着全球疫苗接种完成量的完全重置。</blockquote></p><p>Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.</p><p><blockquote>埃尔克本周在摩根大通年度医疗保健会议上发表讲话时表示，该公司将在第一季度末达到每月2亿剂的生产速度。</blockquote></p><p>It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.</p><p><blockquote>它已经开始向欧洲发货，到第一季度末，总量将达到2700万剂，并向印度尼西亚发货1000万剂，印度尼西亚是它第一次打响武器的地方。</blockquote></p><p>Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn&#39;t going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.</p><p><blockquote>首席商务官John Trizzino告诉雅虎财经，Novavax不会就今年的总剂量提供具体指导，主要是因为它仍在等待更多授权的通过，这将影响总剂量。</blockquote></p><p>As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.</p><p><blockquote>截至周二，Novavax已获得印度尼西亚、印度、欧洲和菲律宾的使用授权，以及世界卫生组织的紧急使用清单。它仍在等待南非、澳大利亚、新西兰、新加坡、日本、阿联酋、英国和加拿大的授权。它还在等待向美国申请紧急使用的批准。食品药品监督管理局，在2021年底提交必要数据后。</blockquote></p><p>Through the WHO emergency listing, the company&#39;s vaccine is now available to 170 countries.</p><p><blockquote>通过世卫组织紧急上市，该公司的疫苗现已可供170个国家使用。</blockquote></p><p>&#34;We worked really hard over the past two years ... and now it&#39;s time to introduce our product to the world,&#34; Trizzino said.</p><p><blockquote>“过去两年我们非常努力……现在是时候向世界介绍我们的产品了，”特里齐诺说。</blockquote></p><p><b>Manufacturing hurdles</b></p><p><blockquote><b>制造障碍</b></blockquote></p><p>Novavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.</p><p><blockquote>当疫情开始时，Novavax是一家苦苦挣扎的后期生物技术公司，但在全球慈善机构和美国政府的帮助下，它转向专注于疫情。</blockquote></p><p>The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.</p><p><blockquote>该公司正在进行流感疫苗的3期临床试验，但未能将RSV疫苗推向市场。</blockquote></p><p>&#34;We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you&#39;re starting out in the hole, if you will, and we had to scale up very, very quickly,&#34; Trizzino said.</p><p><blockquote>“由于在此之前的RSV故障，我们基本上一开始就没有制造能力。所以，如果你愿意的话，你就从洞里开始，我们必须非常非常快地扩大规模，”特里齐诺说。</blockquote></p><p>The company&#39;s manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.</p><p><blockquote>该公司的制造问题在很大程度上导致了过去一年的时间表推迟。Trizzino表示，必须同时管理八个全球站点是一个重大挑战。</blockquote></p><p>&#34;Why didn&#39;t we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,&#34; he said.</p><p><blockquote>“为什么我们不专注于一个设施并大功告成呢？那么，选择什么设施才是正确的？因此，将技术转移到多个设施比我们想象的要付出更多的努力，”他说。</blockquote></p><p>In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.</p><p><blockquote>此外，疫苗平台虽然具有易于储存和运输的优点，但制造起来很复杂。</blockquote></p><p>&#34;It&#39;s a complicated assay, and we underestimated what it would take to develop those assays,&#34; Trizzino said.</p><p><blockquote>“这是一种复杂的检测方法，我们低估了开发这些检测方法所需的费用，”特里齐诺说。</blockquote></p><p>Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.</p><p><blockquote>他说，通常情况下，该公司需要四到六年的时间才能扩大到过去两年的规模。</blockquote></p><p>Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca&#39;s (AZN) vaccine— is helping the company make up for lost time.</p><p><blockquote>现在，与印度血清研究所（该研究所也生产阿斯利康（AZN）疫苗）的合作正在帮助该公司弥补失去的时间。</blockquote></p><p>In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute&#39;s manufacturing quality for doses.</p><p><blockquote>事实上，如果该疫苗在美国获得授权，它将基于发送给其他全球卫生当局的相同数据，依赖于血清研究所的剂量制造质量。</blockquote></p><p>&#34;So it would be Serum product that we would use in the U.S.,&#34; Trizzino said, noting that while the company is U.S.-based, its &#34;success or failure as a company...is not exclusively based in the U.S.&#34;</p><p><blockquote>特里齐诺说：“因此，我们将在美国使用血清产品。”他指出，虽然该公司总部位于美国，但其“作为一家公司的成功或失败……并不完全取决于美国。”</blockquote></p><p>Global vaccine market</p><p><blockquote>全球疫苗市场</blockquote></p><p>Trizzino said that the company&#39;s global focus does not mean the company will be only a provider to low income countries.</p><p><blockquote>Trizzino表示，该公司专注于全球并不意味着该公司将只是低收入国家的供应商。</blockquote></p><p>&#34;People misunderstand the market. It&#39;s not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It&#39;s all at once,&#34; Trizzino said.</p><p><blockquote>“人们误解了市场。这不是典型的疫苗发布，第一年我们在美国上市，两三年后在欧洲上市，三到五年后在世界其他地方上市。这一切都是一次性的，”特里齐诺说。</blockquote></p><p>The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.</p><p><blockquote>该公司失去了在美国第一波疫苗中发挥重要作用的机会，但它仍然有一个小市场——因为该国完全接种疫苗的合格人口的比例徘徊在66%——以及全球机会。</blockquote></p><p></p><p>Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.</p><p><blockquote>Trizzino表示，仅在美国，仅初级剂量就有1.8亿剂的机会。再加上全球范围内的初级剂量和加强剂量，总共有40亿剂的机会。</blockquote></p><p>The potential doesn&#39;t stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.</p><p><blockquote>Trizzino说，潜力还不止于此，并指出可能会有额外的加强剂或每年重新接种疫苗。</blockquote></p><p>&#34;Now, we&#39;re not saying we&#39;re going to capture all that. But what people should take away is that the trend line is that there&#39;s an increase in demand for vaccines, not a decrease,&#34; Trizzino added.</p><p><blockquote>“现在，我们并不是说我们会抓住所有这些。但人们应该记住的是，趋势线是对疫苗的需求增加，而不是减少，”特里齐诺补充道。</blockquote></p><p>The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country&#39;s ability to pay.</p><p><blockquote>与此同时，定价策略并没有反映传统的疫苗分级推出，美国最终可能支付欧洲两倍的费用。相反，定价是基于一个国家的支付能力。</blockquote></p><p>&#34;Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,&#34; Trizzino said.</p><p><blockquote>“基本上，欧洲和美国目前为剂量支付的价格相同。因此，人们需要重新设定他们对商业市场的看法以及需求状况的预期，”特里齐诺说。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html\">Yahoo Finance</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/novavax-ceo-were-going-to-make-a-significant-impact-on-this-covid-pandemic-195631610.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107505154","content_text":"Novavax (NVAX) is waiting for its COVID-19 vaccine to be authorized in the U.S., but with authorizations now in three major markets globally, the biotech company says it's making its mark on the pandemic.\"We're going to make a significant impact on this Covid pandemic,\" CEO Stanley Erck told Yahoo Finance Tuesday.\"The market for primary vaccination — two-dose vaccination which is now being talked about as three-dose vaccination — is unsatisfied,\" Erck said.\"It's not exclusively low income countries, because high income countries need this. We need to get past the vaccine hesitancy,\" he added.If the definition for 'fully-vaccinated' changes to three doses, for both Novavax and mRNA vaccines, it could mean a complete reset in vaccination completions globally.Erck, who spoke at the JPMorgan annual health care conference this week, says the company is going to meet a production speed of 200 million doses per month by the end of the first quarter.It has already begun shipments to Europe, which should total 27 million by the end of the first quarter, as well as a batch of 10 million doses to Indonesia — the site of its first shots in arms.Chief commercial officer John Trizzino told Yahoo Finance that Novavax wasn't going to provide specific guidance on the total number of doses for the year, largely because it is still waiting for more authorizations to come through, which would impact the total doses.As of Tuesday, Novavax has received use authorization in Indonesia, India, Europe and the Philippines, and emergency use listing from the World Health Organization. It is still awaiting authorization in South Africa, Australia, New Zealand, Singapore, Japan, UAE, U.K. and Canada. It is also waiting to get the green light to file for emergency use with the U.S. Food and Drug Administration, after submitting the necessary data at the end of 2021.Through the WHO emergency listing, the company's vaccine is now available to 170 countries.\"We worked really hard over the past two years ... and now it's time to introduce our product to the world,\" Trizzino said.Manufacturing hurdlesNovavax was a struggling late-stage biotech when the pandemic started, but it pivoted to focus on the pandemic with the help of global philanthropies and the U.S. government.The company was working on a Phase 3 clinical trial for its flu vaccine and had failed to bring an RSV vaccine to market.\"We, because of our RSV failures prior to that, we basically started with no manufacturing capacity. So, you're starting out in the hole, if you will, and we had to scale up very, very quickly,\" Trizzino said.The company's manufacturing problems contributed significantly to a delayed timeline in the past year. Trizzino said it was a significant challenge to have to manage eight global sites at one time.\"Why didn't we just focus on one facility and slam dunk it? Well, what would have been the right facility to pick? So, it was more effort than we had assumed to tech transfer to multiple facilities,\" he said.In addition, the vaccine platform, while it offers easy to store and transport benefits, is complicated to make.\"It's a complicated assay, and we underestimated what it would take to develop those assays,\" Trizzino said.Normally, it would have taken the company four to six years to scale up to where it has in the past two, he said.Now, a partnership with the Serum Institute of India — which is also producing AstraZeneca's (AZN) vaccine— is helping the company make up for lost time.In fact, if the vaccine is authorized in the U.S., it will be based off of the same data sent to other global health authorities, relying on the Serum Institute's manufacturing quality for doses.\"So it would be Serum product that we would use in the U.S.,\" Trizzino said, noting that while the company is U.S.-based, its \"success or failure as a company...is not exclusively based in the U.S.\"Global vaccine marketTrizzino said that the company's global focus does not mean the company will be only a provider to low income countries.\"People misunderstand the market. It's not the typical vaccine launch where in year one we get launched in the U.S., and two or three years later it gets launched in Europe, and three to five years later it gets launched to the rest of the world. It's all at once,\" Trizzino said.The company lost an opportunity to play a major role in the initial wave of vaccines in the U.S., but it still has a small market — as the country hovers at 66%of the eligible population fully vaccinated — as well opportunity globally.Trizzino said that represents a 180 million dose opportunity in primary doses alone in the U.S. Add to that primary doses and boosters globally and the total is a 4 billion dose opportunity.The potential doesn't stop there, Trizzino said, noting there could be additional boosters or annual revaccination on the table.\"Now, we're not saying we're going to capture all that. But what people should take away is that the trend line is that there's an increase in demand for vaccines, not a decrease,\" Trizzino added.The pricing strategy, meanwhile, does not reflects traditional tiered rollout of vaccines, where the U.S. can end up paying double what Europe pays. Instead, the pricing is based on a country's ability to pay.\"Basically, Europe and the U.S. are paying the same price for doses right now. So people kind of need to reset their expectations about the way that they think about the commercial market, and what the demand profile looks like,\" Trizzino said.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694288621,"gmtCreate":1641991896037,"gmtModify":1641991896135,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"Go go go!","listText":"Go go go!","text":"Go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694288621","repostId":"1197778610","repostType":2,"repost":{"id":"1197778610","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641989054,"share":"https://www.laohu8.com/m/news/1197778610?lang=zh_CN&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Novavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197778610","media":"Tiger Newspress","summary":"Novavax shares rose nearly 2% in premarket trading.South Korea has authorized the use of Novavax's(N","content":"<p><html><head></head><body>Novavax shares rose nearly 2% in premarket trading.<img src=\"https://static.tigerbbs.com/e1e1f7675223becdeac757160fa927c2\" tg-width=\"723\" tg-height=\"605\" width=\"100%\" height=\"auto\"/>South Korea has authorized the use of Novavax&#39;s(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer&#39;s(NYSE:PFE)antiviral pills.</p><p><blockquote><html><head></head><body>Novavax股价在盘前交易中上涨近2%。韩国已授权使用Novavax（纳斯达克：NVAX）的COVID-19疫苗，并准备分发辉瑞（纽约证券交易所：PFE）的第一种抗病毒药丸。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2022-01-12 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Novavax shares rose nearly 2% in premarket trading.<img src=\"https://static.tigerbbs.com/e1e1f7675223becdeac757160fa927c2\" tg-width=\"723\" tg-height=\"605\" width=\"100%\" height=\"auto\"/>South Korea has authorized the use of Novavax&#39;s(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer&#39;s(NYSE:PFE)antiviral pills.</p><p><blockquote><html><head></head><body>Novavax股价在盘前交易中上涨近2%。韩国已授权使用Novavax（纳斯达克：NVAX）的COVID-19疫苗，并准备分发辉瑞（纽约证券交易所：PFE）的第一种抗病毒药丸。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197778610","content_text":"Novavax shares rose nearly 2% in premarket trading.South Korea has authorized the use of Novavax's(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer's(NYSE:PFE)antiviral pills.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694641623,"gmtCreate":1641969909530,"gmtModify":1641969909530,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"Awesome!&nbsp;","listText":"Awesome!&nbsp;","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694641623","repostId":"2202736976","repostType":2,"isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694641100,"gmtCreate":1641969883226,"gmtModify":1641969883316,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"And yes we have one of them today...South Korea! Yay!","listText":"And yes we have one of them today...South Korea! Yay!","text":"And yes we have one of them today...South Korea! Yay!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694641100","repostId":"1192824861","repostType":2,"repost":{"id":"1192824861","kind":"news","pubTimestamp":1641897395,"share":"https://www.laohu8.com/m/news/1192824861?lang=zh_CN&edition=full","pubTime":"2022-01-11 18:36","market":"us","language":"en","title":"Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192824861","media":"Seeking Alpha","summary":"On Monday, Stanley Erck, the CEO of Novavax  said he expects the company's coronavirus vaccine could","content":"<p><html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.</p><p><blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote></p><p>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.</p><p><blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote></p><p>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.</p><p><blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote></p><p>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.</p><p><blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote></p><p>Several other health agencies across the globe have already given their nod of approval to the vaccine.</p><p><blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote></p><p>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.</p><p><blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote></p><p>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.</p><p><blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote></p><p>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”</p><p><blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote></p><p>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.</p><p><blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote></p><p>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.</p><p><blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-11 18:36</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.</p><p><blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote></p><p>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.</p><p><blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote></p><p>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.</p><p><blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote></p><p>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.</p><p><blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote></p><p>Several other health agencies across the globe have already given their nod of approval to the vaccine.</p><p><blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote></p><p>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.</p><p><blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote></p><p>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.</p><p><blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote></p><p>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”</p><p><blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote></p><p>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.</p><p><blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote></p><p>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.</p><p><blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192824861","content_text":"On Monday, Stanley Erck, the CEO of Novavax  said he expects the company's coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.Several other health agencies across the globe have already given their nod of approval to the vaccine.Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.Bourla also said he didn't know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694116887,"gmtCreate":1641865364071,"gmtModify":1641865364071,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"heavy discounts for the shares we love!&nbsp;","listText":"heavy discounts for the shares we love!&nbsp;","text":"heavy discounts for the shares we love!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694116887","repostId":"2202277188","repostType":4,"isVote":1,"tweetType":1,"viewCount":1632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695446212,"gmtCreate":1641561502882,"gmtModify":1641561502882,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"Looks like Singapore is considering their vaccine too..","listText":"Looks like Singapore is considering their vaccine too..","text":"Looks like Singapore is considering their vaccine too..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695446212","repostId":"2201292411","repostType":2,"isVote":1,"tweetType":1,"viewCount":1367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695028072,"gmtCreate":1641273866277,"gmtModify":1641274312612,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"Have been buying the dips!","listText":"Have been buying the dips!","text":"Have been buying the dips!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695028072","repostId":"1194204182","repostType":2,"repost":{"id":"1194204182","kind":"news","pubTimestamp":1641264319,"share":"https://www.laohu8.com/m/news/1194204182?lang=zh_CN&edition=full","pubTime":"2022-01-04 10:45","market":"us","language":"en","title":"Some Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194204182","media":"InvestorPlace","summary":"The medium-term outlook of NVAX stock remains positive","content":"<p><div> Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023....</p><p><blockquote><div>Novavax（纳斯达克：NVAX）仍准备向全球许多国家出售其冠状病毒疫苗，这可能使其在2022年甚至2023年产生非常强劲的收入....</div></blockquote></p><p>  <a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2022-01-04 10:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023....</p><p><blockquote><div>Novavax（纳斯达克：NVAX）仍准备向全球许多国家出售其冠状病毒疫苗，这可能使其在2022年甚至2023年产生非常强劲的收入....</div></blockquote></p><p>  <a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194204182","content_text":"Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023. Yet NVAX stock has fallen sharply in recent days.That makes the shares very attractive for medium-term investors. Shares tumbled 25% in December alone.On the positive side for Novavax and NVAX stock, on Dec. 20, a European MedicinesAgency (EMA) panel recommended that Novavax be able to market its vaccine for the coronavirus to adults in the EU.As a result of this news, the EMA, the EU’s version of the Food and Drug Administration, is very likely to approve Novavax’s coronavirus vaccine for adults. And since the EU has agreed to purchase up to 200 million doses of Novavax’s vaccine, the approval is likely to lead to significant revenue for the company. And those sales, in turn, will probably lift NVAX stock in the medium term.What’s more, after the EMA’s approval, I think that the FDA is much more likely than not to approve Novavax’s vaccine for three reasons. First, the EMA’s approval does indicate that the vaccine is safe and effective against the coronavirus.Secondly, after the U.S. effectively discouraged the use of Johnson & Johnson’s(NYSE:JNJ) vaccine because of a side effect, I believe that Washington will want to have a shot that can appeal to those Americans who are nervous about the mRNA vaccines made by Pfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA). It is, after all, true that the mRNA shots are based on relatively new technology and that Novavax’s vaccine is based on older, more conventional methods.“The Novavax vaccine has no genetic material, only proteins,” Dr. Diana Florescu, who oversaw the Phase 3 trial of the shot,said in June, according toNebraska Medicine. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”Moreover, the U.S. has funded Novavax in the past and has agreed to purchase 100 million doses from it.On a separate note, the World Health Organization approved Novavax’s shot on Dec. 17, opening the door for many more developing nations to purchase the vaccine.The Mildness of Omicron Will Likely Reduce Demand for Novavax’s JabOn the other hand, the relative mildness of the Omicron variation of Covid-19 is likely to, over the longer run, significantly lower the demand for Novavax’s shot. As evidence of that mildness, consider that a U.K.-based study recently found that those “with the omicron variant are 70% less likely to be hospitalized than those infected with the delta variant,Seeking Alphareported.The relative mildness could very well lower demand for Novavax’s vaccine in many countries. Still, I think there will still be meaningful demand in many nations. After all, many individuals, particularly those who are older and/or have more vulnerable immune systems, get flu shots every year.And among most people, the fear of the coronavirus will likely always be stronger than the fear of the flu, even if there is little or no difference in their risk from the two illnesses. Consequently, I think that there will still be some demand for Novavax’s vaccine, especially in the medium-term, even if omicron proves to be little more risky than the flu for many people.The Bottom Line on NVAX StockIn my opinion, many investors think that Novavax may not get FDA approval for its shot and/or could have difficulties manufacturing and distributing its vaccine.But after the EMA approved the shot, I think there’s an 80% chance that the FDA will also give it a thumbs up. And as I pointed out in my previous column, the drug maker is partnering with the Serum Institute of India on the manufacturing of its Covid-19 vaccine. I believe that the odds are good that Novavax will find multiple other manufacturing and distribution partners.So although the long-term performance of NVAX could be hindered by lower-than-expected demand for its shot, I continue to believe that the shares’ medium-term outlook is favorable, given the partnerships and approvals that the firm likely to obtain during that period.As a result, I urge medium-term, risk-tolerant investors to buy a relatively small amount of the shares on their current weakness.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695000724,"gmtCreate":1641257145373,"gmtModify":1641257145373,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.&nbsp;","listText":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.&nbsp;","text":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695000724","repostId":"2200247876","repostType":2,"isVote":1,"tweetType":1,"viewCount":1165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692504970,"gmtCreate":1641020779605,"gmtModify":1641028860932,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"‌<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021:&nbsp;Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","listText":"‌<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021:&nbsp;Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","text":"‌$Novavax(NVAX)$‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021: Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692504970","isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601658683,"gmtCreate":1638525565944,"gmtModify":1638525863467,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","text":"$Pfizer(PFE)$I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/601658683","isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":601658683,"gmtCreate":1638525565944,"gmtModify":1638525863467,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/PFE\">$Pfizer(PFE)$</a>I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","text":"$Pfizer(PFE)$I think there is a lot of potential in this company since they are already preparing shipments of their antiviral pill for treating COVID-19 and there are numerous reports saying that the pills are less sensitive to variants.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/601658683","isVote":1,"tweetType":1,"viewCount":526,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694116887,"gmtCreate":1641865364071,"gmtModify":1641865364071,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"heavy discounts for the shares we love!&nbsp;","listText":"heavy discounts for the shares we love!&nbsp;","text":"heavy discounts for the shares we love!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694116887","repostId":"2202277188","repostType":4,"isVote":1,"tweetType":1,"viewCount":1632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694288621,"gmtCreate":1641991896037,"gmtModify":1641991896135,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"Go go go!","listText":"Go go go!","text":"Go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694288621","repostId":"1197778610","repostType":2,"repost":{"id":"1197778610","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641989054,"share":"https://www.laohu8.com/m/news/1197778610?lang=zh_CN&edition=full","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Novavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197778610","media":"Tiger Newspress","summary":"Novavax shares rose nearly 2% in premarket trading.South Korea has authorized the use of Novavax's(N","content":"<p><html><head></head><body>Novavax shares rose nearly 2% in premarket trading.<img src=\"https://static.tigerbbs.com/e1e1f7675223becdeac757160fa927c2\" tg-width=\"723\" tg-height=\"605\" width=\"100%\" height=\"auto\"/>South Korea has authorized the use of Novavax&#39;s(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer&#39;s(NYSE:PFE)antiviral pills.</p><p><blockquote><html><head></head><body>Novavax股价在盘前交易中上涨近2%。韩国已授权使用Novavax（纳斯达克：NVAX）的COVID-19疫苗，并准备分发辉瑞（纽约证券交易所：PFE）的第一种抗病毒药丸。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares rose nearly 2% in premarket trading<blockquote>Novavax股价在盘前交易中上涨近2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2022-01-12 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Novavax shares rose nearly 2% in premarket trading.<img src=\"https://static.tigerbbs.com/e1e1f7675223becdeac757160fa927c2\" tg-width=\"723\" tg-height=\"605\" width=\"100%\" height=\"auto\"/>South Korea has authorized the use of Novavax&#39;s(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer&#39;s(NYSE:PFE)antiviral pills.</p><p><blockquote><html><head></head><body>Novavax股价在盘前交易中上涨近2%。韩国已授权使用Novavax（纳斯达克：NVAX）的COVID-19疫苗，并准备分发辉瑞（纽约证券交易所：PFE）的第一种抗病毒药丸。</body></html></blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197778610","content_text":"Novavax shares rose nearly 2% in premarket trading.South Korea has authorized the use of Novavax's(NASDAQ:NVAX)COVID-19 Vaccine, and is preparing to distribute the first of Pfizer's(NYSE:PFE)antiviral pills.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692504970,"gmtCreate":1641020779605,"gmtModify":1641028860932,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"‌<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021:&nbsp;Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","listText":"‌<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021:&nbsp;Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","text":"‌$Novavax(NVAX)$‌For those who are confused with the submisson of final data package and EUA application:31st Dec 2021: Chemistry, manufacturing and controls (CMC) data module submitted to U.S. Food and Drug Administration (FDA), completing final data packages required for emergency use authorization (EUA) application for Novavax' COVID-19 vaccine By 31st Jan 2022: UA application request to be submitted following one month required by FDA EUA guidancehttps://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692504970","isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694754183,"gmtCreate":1642135767949,"gmtModify":1642135767949,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"That is some analysis!","listText":"That is some analysis!","text":"That is some analysis!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694754183","repostId":"1189278661","repostType":4,"repost":{"id":"1189278661","kind":"news","pubTimestamp":1642127310,"share":"https://www.laohu8.com/m/news/1189278661?lang=zh_CN&edition=full","pubTime":"2022-01-14 10:28","market":"us","language":"en","title":"Palantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189278661","media":"Seeking Alpha","summary":"SummaryI respond to reader feedback on my most recent Palantir article.Reader feedback is divided in","content":"<p><html><head></head><body>Summary</p><p><blockquote><html><head></head><body>总结</body></html></blockquote></p><p><ul><li>I respond to reader feedback on my most recent Palantir article.</li><li>Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.</li><li>I stand by my assertion that Palantir is highly overvalued.</li></ul>My previous article on the big-data company <b>Palantir (PLTR)</b>created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company&#39;s stock is difficult, if not impossible, to justify based on the company&#39;s financials.</p><p><blockquote><ul><li>我回应读者对我最近的Palantir文章的反馈。</li><li>读者反馈分为四类：估值、公司亏损、护城河、可扩展性。</li><li>我袖手旁观我的断言，即Palantir被严重高估。</li></ul>我上一篇关于大数据公司的文章<b>帕兰蒂尔(PLTR)</b>引起了不小的轰动。有超过700条评论和大量的（负面）反馈，我认为分享我在这篇文章中收到的一些最重要的问题的想法是合适的。就披露而言，我没有Palantir的空头头寸，也不打算开设空头头寸。我只是认为，根据公司的财务状况，即使不是不可能，也很难证明公司的股票是合理的。</blockquote></p><p><b>My $5 Price Target For Palantir</b></p><p><blockquote><b>我对Palantir的目标价为5美元</b></blockquote></p><p>In my previous article, &#34;Palantir: Fair Value Of $5,&#34; I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.</p><p><blockquote>在我之前的文章“Palantir：公允价值为5美元”中，我声称这家大数据公司从根本上被不合理地高估了。我的理由是，一家像Palantir一样经营时间长的公司应该拥有更好的财务状况，看起来比我们在第十季度报告中看到的要好得多。</blockquote></p><p>My main concern was Palantir&#39;s valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir&#39;s annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir&#39;s valuation appears indefensible.</p><p><blockquote>我主要关心的是Palantir的估值，它要求买家支付20倍的销售额。在正常和更清醒的时期，20的市盈率被认为是很高的。即使考虑到Palantir 30%+的年增长率，支付（预期）销售额的20倍仍然有点牵强，并且需要对销售增长真正实现充满信心。即便如此，Palantir的估值似乎也站不住脚。</blockquote></p><p>I&#39;d like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).</p><p><blockquote>我想借此机会谈谈我收到的一些反馈，涉及我收到最多问题的四个领域（估值、公司亏损、护城河和可扩展性）。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Many readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.</p><p><blockquote>许多读者强烈不同意我的评估。我收到的最常见的问题集中在Palantir实现显着的收入增长，并且由于这种快速增长，Palantir的市值至少应该达到100亿美元。</blockquote></p><p>This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don&#39;t deny that Palantir&#39;s revenue is rapidly increasing. According to the company&#39;s long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir&#39;s outlook was confirmed in the company&#39;s most recent quarterly earnings report, and the company expects 40% growth this year.</p><p><blockquote>这一论点忽略了一个事实，即就估值而言，收入基础的规模与销售增长率同样重要。我也不否认Palantir的收入正在迅速增长。根据公司的长期销售预测，公司的目标是30%的年增长率。Palantir的前景在该公司最新的季度财报中得到证实，该公司预计今年将增长40%。</blockquote></p><p>Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn&#39;t mean the company &#34;should be worth $10 billion.&#34; This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir&#39;s revenue growth rate of 30% should not be overlooked, it is not 100%.</p><p><blockquote>Palantir正在迅速扩张，但收入基础必须与销售增长率一起考虑才能有任何意义。如果我经营一家年销售额为100万美元的企业，并且销售额每年翻一番，这并不意味着这家公司“应该价值100亿美元”。如果不考虑美元收入基础，就无法得出这一结论。虽然Palantir 30%的收入增长率不应被忽视，但它并不是100%。</blockquote></p><p>Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir&#39;s growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.</p><p><blockquote>Palantir的市值为340亿美元，市场预计2021年收入为15.3亿美元，2022年收入为19.9亿美元。这里，隐含的销售倍数为22（2021年预计）和17（2022年预计）。Palantir的增长倍数过高，面临进一步收缩的风险。为一项业务支付大约20倍销售额的费用，即使它是完美的，也不仅仅是一种延伸；这可能是一次自杀任务。</blockquote></p><p><b>IPO And Losses</b></p><p><blockquote><b>首次公开发售及亏损</b></blockquote></p><p>In response to my previous article, I received a lot of feedback along the lines of &#34;Palantir is investing money, and this money will come back later in terms of free cash flow,&#34; or &#34;Palantir just had its IPO, and profits are not expected.&#34;</p><p><blockquote>针对我之前的文章，我收到了很多反馈，大意是“Palantir正在投资，这笔钱稍后会在自由现金流方面回来”，或者“Palantir刚刚进行了IPO，利润没有预期。”</blockquote></p><p>Both arguments, in my opinion, are flawed.</p><p><blockquote>在我看来，这两种观点都有缺陷。</blockquote></p><p>Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market&#39;s opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.</p><p><blockquote>Palantir并不是一家最近上市并正在寻找资本投资的年轻公司。Palantir自2003年开始营业，至今尚未盈利。事实上，公司内部人士已经利用今年市场的机会，在2021年大量抛售A类股票。这篇文章是任何Palantir投资者的必读之作，深入探讨了今年出现的内幕销售情况。</blockquote></p><p>In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.</p><p><blockquote>换句话说，拥有股权的内部人士正在通过向毫无戒心的散户投资者抛售股票来套现，这些散户投资者愿意为一家亏损公司支付20倍的销售额。这个故事在我一生中已经被讲过好几次了。</blockquote></p><p>Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir&#39;s losses in 2021 are &#34;only&#34; $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.</p><p><blockquote>正如我在上一篇文章中解释的那样，Palantir今年不仅亏损。在其存在的整个过程中，这家大数据公司一直在亏损，并以惊人的速度累积亏损。Palantir 2021年的亏损“仅”为3.64亿美元。到9月底亏损可能会大大低于去年，但仍然是亏损。</blockquote></p><p></p><p>And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company&#39;s balance sheet and is deducted from stockholders&#39; equity. It displays the total of a company&#39;s losses accumulated during its active period of operation. Palantir&#39;s accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman&#39;s terms, Palantir has depleted 70% of its investor capital. That&#39;s a frightening figure.</p><p><blockquote>而且，在企业估值中，利润/亏损应该和销售预测一样重要，在大多数情况下，销售预测是积极的。我认为我之前的Palantir文章中忽略了一点，那就是该公司的累计亏损为53亿美元。会计规则要求累计赤字出现在公司的资产负债表上，并从股东权益中扣除。它显示公司在其活跃运营期间累计的损失总额。Palantir的累计赤字总额为53亿美元，而实收资本总额为76亿美元。通俗地说，Palantir已经耗尽了70%的投资者资本。那是一个可怕的数字。</blockquote></p><p>Concerning the statement &#34;Palantir is investing in its growth and will recoup its investment later&#34;: Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn&#39;t some of the money invested 10 or more years ago have already returned?</p><p><blockquote>关于“Palantir正在投资于其增长，并将在稍后收回投资”的说法：Palantir已经陷入这一阶段近二十年，公司仍然没有盈利。10年或更长时间前投资的一些钱不是应该已经有回报了吗？</blockquote></p><p>The magnitude of the company&#39;s accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir&#39;s capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?</p><p><blockquote>该公司累计赤字的规模以及长达二十年的亏损累积时间令人难以置信，引发了人们对Palantir资本配置的严重担忧。如果我们去一家有20年商业亏损历史的银行，你或我有资格获得多少信贷？</blockquote></p><p><b>Moat</b></p><p><blockquote><b>护城河</b></blockquote></p><p>Questions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company&#39;s clients include numerous government agencies. The implication here appears to be that Palantir&#39;s relationship network serves as a moat.</p><p><blockquote>有人质疑为什么我认为Palantir的业务缺乏重要的护城河，尽管该公司的客户包括众多政府机构。这里的含义似乎是Palantir的关系网络充当了护城河。</blockquote></p><p>Palantir works with a number of cash-rich government agencies that use the company&#39;s technology platforms across the board. I don&#39;t deny that Palantir&#39;s platforms, or &#34;foundries,&#34; as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.</p><p><blockquote>Palantir与许多现金充裕的政府机构合作，这些机构全面使用该公司的技术平台。我不否认Palantir的平台（或该公司所称的“代工厂”）执行关键的数据管理和分析功能。Palantir最近获得了美国陆军和太空系统司令部价值数百万美元的合同。陆军合同价值超过8亿美元，而太空系统司令部合同价值4300万美元。</blockquote></p><p>That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir&#39;s &#34;relationships&#34; with the government. To be honest, this would be illegal. As a result, the notion that the company&#39;s relationships aid Palantir in the construction of a moat is false.</p><p><blockquote>话虽如此，我并不否认Palantir成功获得了合同。我的意思是Palantir必须经过竞争流程才能中标。合同的授予不是基于Palantir与政府的“关系”。老实说，这是违法的。因此，认为该公司的关系有助于Palantir建立护城河的想法是错误的。</blockquote></p><p><b>Scalability</b></p><p><blockquote><b>可扩展性</b></blockquote></p><p>Some of the comments I received focused on Palantir&#39;s ability to capitalize on the big data revolution, as well as Palantir&#39;s scalability.</p><p><blockquote>我收到的一些评论集中在Palantir利用大数据革命的能力以及Palantir的可扩展性上。</blockquote></p><p>But where is this scalability, which is frequently mentioned as a reason to buy the stock?</p><p><blockquote>但这种经常被提及作为购买股票理由的可扩展性在哪里呢？</blockquote></p><p>Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of &#34;scale.&#34;<img src=\"https://static.tigerbbs.com/64df144337f177af7f37125517af8d56\" tg-width=\"640\" tg-height=\"143\" width=\"100%\" height=\"auto\"/>The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don&#39;t see real scalability with Palantir.</p><p><blockquote>Palantir表示，它需要人员向客户介绍其代工厂的功能。就人力资源而言，需要客户试点的软件既耗时又昂贵。这是“规模”的倒数。降低边际成本的能力是可伸缩性的一个关键特征。有了足够大的客户群，边际成本可以降到零。Palantir的情况并非如此，它必须向客户提供所部署平台的复杂性或引导他们了解新功能。在我看来，Palantir更类似于一家同时销售软件产品的IT咨询公司。但我认为Palantir没有真正的可扩展性。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>Palantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir&#39;s stock remains wildly overpriced.</p><p><blockquote>Palantir不是一家盈利的公司。Palantir被严重稀释。Palantir的内部人士正在抛售。即使年收入增长30%，Palantir的股价仍然被严重高估。</blockquote></p><p>High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.</p><p><blockquote>高市盈率股票，尤其是科技行业的股票，最近开始盘整，随着投资者不太愿意为那些股价飞涨但未能达到高预期的企业支付高价，更多的下跌即将到来。</blockquote></p><p>Palantir&#39;s valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir&#39;s market price.</p><p><blockquote>Palantir的估值是一个巨大的问题，尽管这家大数据公司在一个被大肆宣传的性感行业运营，但业务基本面根本无法证明Palantir的市场价格是合理的。</blockquote></p><p><b>My Conclusion</b></p><p><blockquote><b>我的结论</b></blockquote></p><p>I&#39;m not saying Palantir doesn&#39;t have significant annual sales growth. I&#39;m not saying Palantir&#39;s products are useless to the government. What I am saying is that Palantir&#39;s loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn&#39;t deserve this kind of sales multiple.</p><p><blockquote>我并不是说Palantir的年销售额没有显着增长。我并不是说Palantir的产品对政府毫无用处。我想说的是，Palantir的亏损业务不值得20倍的销售倍数。即使盈利，也不值得这样的销售倍数。</blockquote></p><p></p><p>That&#39;s why I&#39;m sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.</p><p><blockquote>这就是为什么我坚持Palantir 5美元的目标价。5美元的目标价意味着100亿美元的市场估值和5的销售倍数，这仍然是非常慷慨的。由于业务损失的持续存在，不幸的是，市盈率在这里不适用。我相信大多数反馈都是善意的，但牛市案例仍然存在一些严重缺陷。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: A Defense Of My $5 Price Target<blockquote>Palantir：为我的5美元目标价辩护</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-14 10:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Summary</p><p><blockquote><html><head></head><body>总结</body></html></blockquote></p><p><ul><li>I respond to reader feedback on my most recent Palantir article.</li><li>Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.</li><li>I stand by my assertion that Palantir is highly overvalued.</li></ul>My previous article on the big-data company <b>Palantir (PLTR)</b>created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company&#39;s stock is difficult, if not impossible, to justify based on the company&#39;s financials.</p><p><blockquote><ul><li>我回应读者对我最近的Palantir文章的反馈。</li><li>读者反馈分为四类：估值、公司亏损、护城河、可扩展性。</li><li>我袖手旁观我的断言，即Palantir被严重高估。</li></ul>我上一篇关于大数据公司的文章<b>帕兰蒂尔(PLTR)</b>引起了不小的轰动。有超过700条评论和大量的（负面）反馈，我认为分享我在这篇文章中收到的一些最重要的问题的想法是合适的。就披露而言，我没有Palantir的空头头寸，也不打算开设空头头寸。我只是认为，根据公司的财务状况，即使不是不可能，也很难证明公司的股票是合理的。</blockquote></p><p><b>My $5 Price Target For Palantir</b></p><p><blockquote><b>我对Palantir的目标价为5美元</b></blockquote></p><p>In my previous article, &#34;Palantir: Fair Value Of $5,&#34; I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.</p><p><blockquote>在我之前的文章“Palantir：公允价值为5美元”中，我声称这家大数据公司从根本上被不合理地高估了。我的理由是，一家像Palantir一样经营时间长的公司应该拥有更好的财务状况，看起来比我们在第十季度报告中看到的要好得多。</blockquote></p><p>My main concern was Palantir&#39;s valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir&#39;s annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir&#39;s valuation appears indefensible.</p><p><blockquote>我主要关心的是Palantir的估值，它要求买家支付20倍的销售额。在正常和更清醒的时期，20的市盈率被认为是很高的。即使考虑到Palantir 30%+的年增长率，支付（预期）销售额的20倍仍然有点牵强，并且需要对销售增长真正实现充满信心。即便如此，Palantir的估值似乎也站不住脚。</blockquote></p><p>I&#39;d like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).</p><p><blockquote>我想借此机会谈谈我收到的一些反馈，涉及我收到最多问题的四个领域（估值、公司亏损、护城河和可扩展性）。</blockquote></p><p><b>Valuation</b></p><p><blockquote><b>估值</b></blockquote></p><p>Many readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.</p><p><blockquote>许多读者强烈不同意我的评估。我收到的最常见的问题集中在Palantir实现显着的收入增长，并且由于这种快速增长，Palantir的市值至少应该达到100亿美元。</blockquote></p><p>This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don&#39;t deny that Palantir&#39;s revenue is rapidly increasing. According to the company&#39;s long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir&#39;s outlook was confirmed in the company&#39;s most recent quarterly earnings report, and the company expects 40% growth this year.</p><p><blockquote>这一论点忽略了一个事实，即就估值而言，收入基础的规模与销售增长率同样重要。我也不否认Palantir的收入正在迅速增长。根据公司的长期销售预测，公司的目标是30%的年增长率。Palantir的前景在该公司最新的季度财报中得到证实，该公司预计今年将增长40%。</blockquote></p><p>Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn&#39;t mean the company &#34;should be worth $10 billion.&#34; This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir&#39;s revenue growth rate of 30% should not be overlooked, it is not 100%.</p><p><blockquote>Palantir正在迅速扩张，但收入基础必须与销售增长率一起考虑才能有任何意义。如果我经营一家年销售额为100万美元的企业，并且销售额每年翻一番，这并不意味着这家公司“应该价值100亿美元”。如果不考虑美元收入基础，就无法得出这一结论。虽然Palantir 30%的收入增长率不应被忽视，但它并不是100%。</blockquote></p><p>Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir&#39;s growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.</p><p><blockquote>Palantir的市值为340亿美元，市场预计2021年收入为15.3亿美元，2022年收入为19.9亿美元。这里，隐含的销售倍数为22（2021年预计）和17（2022年预计）。Palantir的增长倍数过高，面临进一步收缩的风险。为一项业务支付大约20倍销售额的费用，即使它是完美的，也不仅仅是一种延伸；这可能是一次自杀任务。</blockquote></p><p><b>IPO And Losses</b></p><p><blockquote><b>首次公开发售及亏损</b></blockquote></p><p>In response to my previous article, I received a lot of feedback along the lines of &#34;Palantir is investing money, and this money will come back later in terms of free cash flow,&#34; or &#34;Palantir just had its IPO, and profits are not expected.&#34;</p><p><blockquote>针对我之前的文章，我收到了很多反馈，大意是“Palantir正在投资，这笔钱稍后会在自由现金流方面回来”，或者“Palantir刚刚进行了IPO，利润没有预期。”</blockquote></p><p>Both arguments, in my opinion, are flawed.</p><p><blockquote>在我看来，这两种观点都有缺陷。</blockquote></p><p>Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market&#39;s opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.</p><p><blockquote>Palantir并不是一家最近上市并正在寻找资本投资的年轻公司。Palantir自2003年开始营业，至今尚未盈利。事实上，公司内部人士已经利用今年市场的机会，在2021年大量抛售A类股票。这篇文章是任何Palantir投资者的必读之作，深入探讨了今年出现的内幕销售情况。</blockquote></p><p>In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.</p><p><blockquote>换句话说，拥有股权的内部人士正在通过向毫无戒心的散户投资者抛售股票来套现，这些散户投资者愿意为一家亏损公司支付20倍的销售额。这个故事在我一生中已经被讲过好几次了。</blockquote></p><p>Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir&#39;s losses in 2021 are &#34;only&#34; $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.</p><p><blockquote>正如我在上一篇文章中解释的那样，Palantir今年不仅亏损。在其存在的整个过程中，这家大数据公司一直在亏损，并以惊人的速度累积亏损。Palantir 2021年的亏损“仅”为3.64亿美元。到9月底亏损可能会大大低于去年，但仍然是亏损。</blockquote></p><p></p><p>And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company&#39;s balance sheet and is deducted from stockholders&#39; equity. It displays the total of a company&#39;s losses accumulated during its active period of operation. Palantir&#39;s accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman&#39;s terms, Palantir has depleted 70% of its investor capital. That&#39;s a frightening figure.</p><p><blockquote>而且，在企业估值中，利润/亏损应该和销售预测一样重要，在大多数情况下，销售预测是积极的。我认为我之前的Palantir文章中忽略了一点，那就是该公司的累计亏损为53亿美元。会计规则要求累计赤字出现在公司的资产负债表上，并从股东权益中扣除。它显示公司在其活跃运营期间累计的损失总额。Palantir的累计赤字总额为53亿美元，而实收资本总额为76亿美元。通俗地说，Palantir已经耗尽了70%的投资者资本。那是一个可怕的数字。</blockquote></p><p>Concerning the statement &#34;Palantir is investing in its growth and will recoup its investment later&#34;: Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn&#39;t some of the money invested 10 or more years ago have already returned?</p><p><blockquote>关于“Palantir正在投资于其增长，并将在稍后收回投资”的说法：Palantir已经陷入这一阶段近二十年，公司仍然没有盈利。10年或更长时间前投资的一些钱不是应该已经有回报了吗？</blockquote></p><p>The magnitude of the company&#39;s accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir&#39;s capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?</p><p><blockquote>该公司累计赤字的规模以及长达二十年的亏损累积时间令人难以置信，引发了人们对Palantir资本配置的严重担忧。如果我们去一家有20年商业亏损历史的银行，你或我有资格获得多少信贷？</blockquote></p><p><b>Moat</b></p><p><blockquote><b>护城河</b></blockquote></p><p>Questions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company&#39;s clients include numerous government agencies. The implication here appears to be that Palantir&#39;s relationship network serves as a moat.</p><p><blockquote>有人质疑为什么我认为Palantir的业务缺乏重要的护城河，尽管该公司的客户包括众多政府机构。这里的含义似乎是Palantir的关系网络充当了护城河。</blockquote></p><p>Palantir works with a number of cash-rich government agencies that use the company&#39;s technology platforms across the board. I don&#39;t deny that Palantir&#39;s platforms, or &#34;foundries,&#34; as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.</p><p><blockquote>Palantir与许多现金充裕的政府机构合作，这些机构全面使用该公司的技术平台。我不否认Palantir的平台（或该公司所称的“代工厂”）执行关键的数据管理和分析功能。Palantir最近获得了美国陆军和太空系统司令部价值数百万美元的合同。陆军合同价值超过8亿美元，而太空系统司令部合同价值4300万美元。</blockquote></p><p>That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir&#39;s &#34;relationships&#34; with the government. To be honest, this would be illegal. As a result, the notion that the company&#39;s relationships aid Palantir in the construction of a moat is false.</p><p><blockquote>话虽如此，我并不否认Palantir成功获得了合同。我的意思是Palantir必须经过竞争流程才能中标。合同的授予不是基于Palantir与政府的“关系”。老实说，这是违法的。因此，认为该公司的关系有助于Palantir建立护城河的想法是错误的。</blockquote></p><p><b>Scalability</b></p><p><blockquote><b>可扩展性</b></blockquote></p><p>Some of the comments I received focused on Palantir&#39;s ability to capitalize on the big data revolution, as well as Palantir&#39;s scalability.</p><p><blockquote>我收到的一些评论集中在Palantir利用大数据革命的能力以及Palantir的可扩展性上。</blockquote></p><p>But where is this scalability, which is frequently mentioned as a reason to buy the stock?</p><p><blockquote>但这种经常被提及作为购买股票理由的可扩展性在哪里呢？</blockquote></p><p>Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of &#34;scale.&#34;<img src=\"https://static.tigerbbs.com/64df144337f177af7f37125517af8d56\" tg-width=\"640\" tg-height=\"143\" width=\"100%\" height=\"auto\"/>The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don&#39;t see real scalability with Palantir.</p><p><blockquote>Palantir表示，它需要人员向客户介绍其代工厂的功能。就人力资源而言，需要客户试点的软件既耗时又昂贵。这是“规模”的倒数。降低边际成本的能力是可伸缩性的一个关键特征。有了足够大的客户群，边际成本可以降到零。Palantir的情况并非如此，它必须向客户提供所部署平台的复杂性或引导他们了解新功能。在我看来，Palantir更类似于一家同时销售软件产品的IT咨询公司。但我认为Palantir没有真正的可扩展性。</blockquote></p><p><b>Risks</b></p><p><blockquote><b>风险</b></blockquote></p><p>Palantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir&#39;s stock remains wildly overpriced.</p><p><blockquote>Palantir不是一家盈利的公司。Palantir被严重稀释。Palantir的内部人士正在抛售。即使年收入增长30%，Palantir的股价仍然被严重高估。</blockquote></p><p>High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.</p><p><blockquote>高市盈率股票，尤其是科技行业的股票，最近开始盘整，随着投资者不太愿意为那些股价飞涨但未能达到高预期的企业支付高价，更多的下跌即将到来。</blockquote></p><p>Palantir&#39;s valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir&#39;s market price.</p><p><blockquote>Palantir的估值是一个巨大的问题，尽管这家大数据公司在一个被大肆宣传的性感行业运营，但业务基本面根本无法证明Palantir的市场价格是合理的。</blockquote></p><p><b>My Conclusion</b></p><p><blockquote><b>我的结论</b></blockquote></p><p>I&#39;m not saying Palantir doesn&#39;t have significant annual sales growth. I&#39;m not saying Palantir&#39;s products are useless to the government. What I am saying is that Palantir&#39;s loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn&#39;t deserve this kind of sales multiple.</p><p><blockquote>我并不是说Palantir的年销售额没有显着增长。我并不是说Palantir的产品对政府毫无用处。我想说的是，Palantir的亏损业务不值得20倍的销售倍数。即使盈利，也不值得这样的销售倍数。</blockquote></p><p></p><p>That&#39;s why I&#39;m sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.</p><p><blockquote>这就是为什么我坚持Palantir 5美元的目标价。5美元的目标价意味着100亿美元的市场估值和5的销售倍数，这仍然是非常慷慨的。由于业务损失的持续存在，不幸的是，市盈率在这里不适用。我相信大多数反馈都是善意的，但牛市案例仍然存在一些严重缺陷。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4479466-palantir-a-defense-of-my-5-price-target\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4479466-palantir-a-defense-of-my-5-price-target","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189278661","content_text":"SummaryI respond to reader feedback on my most recent Palantir article.Reader feedback is divided into four categories: valuation, company losses, moat, and scalability.I stand by my assertion that Palantir is highly overvalued.My previous article on the big-data company Palantir (PLTR)created quite a stir. With over 700 comments and a significant amount of (negative) feedback, I believe it is appropriate to share my thoughts on some of the most important questions I have received in this article. In terms of disclosure, I do not have a short position in Palantir and do not intend to open one. I simply believe that the company's stock is difficult, if not impossible, to justify based on the company's financials.My $5 Price Target For PalantirIn my previous article, \"Palantir: Fair Value Of $5,\" I claimed that the big-data company was fundamentally and unjustifiably overvalued. My reasoning was that a company that has been in business for as long as Palantir should have much better financials in place that look significantly better than what we see in the 10Q quarterly reports.My main concern was Palantir's valuation, which requires buyers to pay a sales multiple of twenty. A P/E ratio of 20 would be considered high in normal and more sober times. Even allowing for Palantir's annual growth rate of 30%+, paying 20 times (expected) sales is still a bit of a stretch and requires a lot of faith that the sales growth will actually materialize. Even if it does, Palantir's valuation appears indefensible.I'd like to take this opportunity to address some of the feedback I received regarding the four areas where I received the most questions (valuation, company losses, moat and scalability).ValuationMany readers strongly disagreed with my assessment. The most common question I received centered on the idea that Palantir achieves significant revenue growth and that, as a result of this rapid growth, Palantir deserves a market capitalization of at least $10 billion.This argument ignores the fact that, for valuation purposes, the size of the revenue base is just as important as the rate of sales growth. I also don't deny that Palantir's revenue is rapidly increasing. According to the company's long-term sales forecast, the company is aiming for a 30% annual growth rate. Palantir's outlook was confirmed in the company's most recent quarterly earnings report, and the company expects 40% growth this year.Palantir is rapidly expanding, but the revenue base must be considered alongside the sales growth rate for any sense to be made. If I run a business with $1 million in annual sales and double my sales every year, that doesn't mean the company \"should be worth $10 billion.\" This conclusion cannot be reached without taking into account the dollar revenue base. While Palantir's revenue growth rate of 30% should not be overlooked, it is not 100%.Palantir has a market capitalization of $34 billion, and the market expects revenue of $1.53 billion in 2021 and $1.99 billion in 2022. Here, the implied sales multiples are 22 (2021e) and 17 (2022e). Palantir's growth multiples are excessive and are at risk of further contraction. Paying around 20 times sales for a business, even if it is perfect, is more than a stretch; it may be a suicide mission.IPO And LossesIn response to my previous article, I received a lot of feedback along the lines of \"Palantir is investing money, and this money will come back later in terms of free cash flow,\" or \"Palantir just had its IPO, and profits are not expected.\"Both arguments, in my opinion, are flawed.Palantir is not a young company that recently went public and is looking for capital to invest. Palantir has been in business since 2003 and has yet to make a profit. In fact, company insiders have taken advantage of the market's opportunity this year to sell a large number of Class A shares in 2021.This article, which is a must-read for any Palantir investor, delves deeper into the insider sales situation that has emerged this year.In other words, insiders with equity stakes are cashing out by dumping shares on unsuspecting retail investors willing to pay 20 times sales for a loss-making company. That story has been told to me several times in my life.Palantir is not only losing money this year, as I explained in my previous article. Throughout its existence, the big-data company has suffered losses and accumulated losses at an alarming rate. Palantir's losses in 2021 are \"only\" $364 million. The loss may be much lower than last year by the end of September, but it is still a loss.And, in business valuation, profits/losses should be just as important as sales forecast, which, in most cases, is positive. The point that I believe was overlooked in my previous Palantir article is that the company has $5.3 billion in accumulated losses. Accounting rules require an accumulated deficit to appear on a company's balance sheet and is deducted from stockholders' equity. It displays the total of a company's losses accumulated during its active period of operation. Palantir's accumulated deficits total $5.3 billion, compared to $7.6 billion in total paid-in capital. In layman's terms, Palantir has depleted 70% of its investor capital. That's a frightening figure.Concerning the statement \"Palantir is investing in its growth and will recoup its investment later\": Palantir has been stuck in this phase for nearly two decades, and the company is still not profitable. Shouldn't some of the money invested 10 or more years ago have already returned?The magnitude of the company's accumulated deficit, as well as the incredibly long period of time, two decades, during which losses have accumulated, raise serious concerns about Palantir's capital allocation. How much credit would you or I qualify for if we went to a bank with a 20-year history of making business losses?MoatQuestions have been raised about why I believe Palantir lacks a significant moat in its business, despite the fact that the company's clients include numerous government agencies. The implication here appears to be that Palantir's relationship network serves as a moat.Palantir works with a number of cash-rich government agencies that use the company's technology platforms across the board. I don't deny that Palantir's platforms, or \"foundries,\" as the company refers to them, perform critical data management and analytics functions. Palantir was recently awarded contracts worth millions of dollars by the United States Army and the Space Systems Command. The Army contract is worth more than $800 million, while the Space Systems Command contract is worth $43 million.That being said, I do not deny that Palantir has been successful in obtaining contract awards. What I mean is that Palantir must go through competitive processes in order to win bids. Contracts are not awarded based on Palantir's \"relationships\" with the government. To be honest, this would be illegal. As a result, the notion that the company's relationships aid Palantir in the construction of a moat is false.ScalabilitySome of the comments I received focused on Palantir's ability to capitalize on the big data revolution, as well as Palantir's scalability.But where is this scalability, which is frequently mentioned as a reason to buy the stock?Palantir has stated that it requires personnel to walk customers through the functionality of its foundries. Software that necessitates customer pilots is both time consuming and costly in terms of human resources. That is the inverse of \"scale.\"The ability to have decreasing marginal costs is a key feature of scalability. With a large enough customer base, marginal costs can be reduced to zero. This is not the case for Palantir, which must be available to clients to teach them the intricacies of the deployed platforms or walk them through new functionalities. Palantir, in my opinion, is more akin to an IT consulting firm that also sells software products. But I don't see real scalability with Palantir.RisksPalantir is not a profitable company. Palantir is heavily diluted. Insiders at Palantir are selling. Even with 30% annual revenue growth, Palantir's stock remains wildly overpriced.High-multiple stocks, particularly in the technology sector, have recently begun to consolidate, and more downside is on the way as investors become less willing to pay top dollar for businesses that have flown high but failed to meet high expectations.Palantir's valuation is a huge issue, and despite the fact that the big-data company operates in a sexy industry with a lot of hype, the business fundamentals simply do not justify Palantir's market price.My ConclusionI'm not saying Palantir doesn't have significant annual sales growth. I'm not saying Palantir's products are useless to the government. What I am saying is that Palantir's loss-making business does not merit a sales multiple of 20. Even if it was profitable, it wouldn't deserve this kind of sales multiple.That's why I'm sticking to my $5 price target for Palantir. A $5 price target implies a $10 billion market valuation and a sales multiple of 5, which is still more than generous. Due to the persistence of business losses, an earnings multiple is unfortunately inapplicable here. I believe that the majority of the feedback was well-intentioned, but the bull case still has some serious flaws.","news_type":1,"symbols_score_info":{"PLTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1558,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694436535,"gmtCreate":1642070803449,"gmtModify":1642070803511,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"cant wait for their earning report...","listText":"cant wait for their earning report...","text":"cant wait for their earning report...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694436535","repostId":"1107505154","repostType":2,"isVote":1,"tweetType":1,"viewCount":1844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694641623,"gmtCreate":1641969909530,"gmtModify":1641969909530,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"Awesome!&nbsp;","listText":"Awesome!&nbsp;","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694641623","repostId":"2202736976","repostType":2,"isVote":1,"tweetType":1,"viewCount":1340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694641100,"gmtCreate":1641969883226,"gmtModify":1641969883316,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"And yes we have one of them today...South Korea! Yay!","listText":"And yes we have one of them today...South Korea! Yay!","text":"And yes we have one of them today...South Korea! Yay!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694641100","repostId":"1192824861","repostType":2,"repost":{"id":"1192824861","kind":"news","pubTimestamp":1641897395,"share":"https://www.laohu8.com/m/news/1192824861?lang=zh_CN&edition=full","pubTime":"2022-01-11 18:36","market":"us","language":"en","title":"Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192824861","media":"Seeking Alpha","summary":"On Monday, Stanley Erck, the CEO of Novavax  said he expects the company's coronavirus vaccine could","content":"<p><html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.</p><p><blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote></p><p>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.</p><p><blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote></p><p>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.</p><p><blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote></p><p>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.</p><p><blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote></p><p>Several other health agencies across the globe have already given their nod of approval to the vaccine.</p><p><blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote></p><p>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.</p><p><blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote></p><p>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.</p><p><blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote></p><p>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”</p><p><blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote></p><p>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.</p><p><blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote></p><p>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.</p><p><blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2022-01-11 18:36</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.</p><p><blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote></p><p>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.</p><p><blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote></p><p>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.</p><p><blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote></p><p>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.</p><p><blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote></p><p>Several other health agencies across the globe have already given their nod of approval to the vaccine.</p><p><blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote></p><p>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.</p><p><blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote></p><p>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.</p><p><blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote></p><p>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”</p><p><blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote></p><p>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.</p><p><blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote></p><p>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.</p><p><blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192824861","content_text":"On Monday, Stanley Erck, the CEO of Novavax  said he expects the company's coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.Several other health agencies across the globe have already given their nod of approval to the vaccine.Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.Bourla also said he didn't know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695446212,"gmtCreate":1641561502882,"gmtModify":1641561502882,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"Looks like Singapore is considering their vaccine too..","listText":"Looks like Singapore is considering their vaccine too..","text":"Looks like Singapore is considering their vaccine too..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695446212","repostId":"2201292411","repostType":2,"isVote":1,"tweetType":1,"viewCount":1367,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695028072,"gmtCreate":1641273866277,"gmtModify":1641274312612,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"Have been buying the dips!","listText":"Have been buying the dips!","text":"Have been buying the dips!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695028072","repostId":"1194204182","repostType":2,"repost":{"id":"1194204182","kind":"news","pubTimestamp":1641264319,"share":"https://www.laohu8.com/m/news/1194204182?lang=zh_CN&edition=full","pubTime":"2022-01-04 10:45","market":"us","language":"en","title":"Some Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194204182","media":"InvestorPlace","summary":"The medium-term outlook of NVAX stock remains positive","content":"<p><div> Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023....</p><p><blockquote><div>Novavax（纳斯达克：NVAX）仍准备向全球许多国家出售其冠状病毒疫苗，这可能使其在2022年甚至2023年产生非常强劲的收入....</div></blockquote></p><p>  <a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Investors Should Buy Novavax Stock on the Dip<blockquote>一些投资者应该逢低买入Novavax股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2022-01-04 10:45</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023....</p><p><blockquote><div>Novavax（纳斯达克：NVAX）仍准备向全球许多国家出售其冠状病毒疫苗，这可能使其在2022年甚至2023年产生非常强劲的收入....</div></blockquote></p><p>  <a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194204182","content_text":"Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023. Yet NVAX stock has fallen sharply in recent days.That makes the shares very attractive for medium-term investors. Shares tumbled 25% in December alone.On the positive side for Novavax and NVAX stock, on Dec. 20, a European MedicinesAgency (EMA) panel recommended that Novavax be able to market its vaccine for the coronavirus to adults in the EU.As a result of this news, the EMA, the EU’s version of the Food and Drug Administration, is very likely to approve Novavax’s coronavirus vaccine for adults. And since the EU has agreed to purchase up to 200 million doses of Novavax’s vaccine, the approval is likely to lead to significant revenue for the company. And those sales, in turn, will probably lift NVAX stock in the medium term.What’s more, after the EMA’s approval, I think that the FDA is much more likely than not to approve Novavax’s vaccine for three reasons. First, the EMA’s approval does indicate that the vaccine is safe and effective against the coronavirus.Secondly, after the U.S. effectively discouraged the use of Johnson & Johnson’s(NYSE:JNJ) vaccine because of a side effect, I believe that Washington will want to have a shot that can appeal to those Americans who are nervous about the mRNA vaccines made by Pfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA). It is, after all, true that the mRNA shots are based on relatively new technology and that Novavax’s vaccine is based on older, more conventional methods.“The Novavax vaccine has no genetic material, only proteins,” Dr. Diana Florescu, who oversaw the Phase 3 trial of the shot,said in June, according toNebraska Medicine. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”Moreover, the U.S. has funded Novavax in the past and has agreed to purchase 100 million doses from it.On a separate note, the World Health Organization approved Novavax’s shot on Dec. 17, opening the door for many more developing nations to purchase the vaccine.The Mildness of Omicron Will Likely Reduce Demand for Novavax’s JabOn the other hand, the relative mildness of the Omicron variation of Covid-19 is likely to, over the longer run, significantly lower the demand for Novavax’s shot. As evidence of that mildness, consider that a U.K.-based study recently found that those “with the omicron variant are 70% less likely to be hospitalized than those infected with the delta variant,Seeking Alphareported.The relative mildness could very well lower demand for Novavax’s vaccine in many countries. Still, I think there will still be meaningful demand in many nations. After all, many individuals, particularly those who are older and/or have more vulnerable immune systems, get flu shots every year.And among most people, the fear of the coronavirus will likely always be stronger than the fear of the flu, even if there is little or no difference in their risk from the two illnesses. Consequently, I think that there will still be some demand for Novavax’s vaccine, especially in the medium-term, even if omicron proves to be little more risky than the flu for many people.The Bottom Line on NVAX StockIn my opinion, many investors think that Novavax may not get FDA approval for its shot and/or could have difficulties manufacturing and distributing its vaccine.But after the EMA approved the shot, I think there’s an 80% chance that the FDA will also give it a thumbs up. And as I pointed out in my previous column, the drug maker is partnering with the Serum Institute of India on the manufacturing of its Covid-19 vaccine. I believe that the odds are good that Novavax will find multiple other manufacturing and distribution partners.So although the long-term performance of NVAX could be hindered by lower-than-expected demand for its shot, I continue to believe that the shares’ medium-term outlook is favorable, given the partnerships and approvals that the firm likely to obtain during that period.As a result, I urge medium-term, risk-tolerant investors to buy a relatively small amount of the shares on their current weakness.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2019,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":695000724,"gmtCreate":1641257145373,"gmtModify":1641257145373,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100909250192760","idStr":"4100909250192760"},"themes":[],"htmlText":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.&nbsp;","listText":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.&nbsp;","text":"Awesome! looks like several investment sites are starting to raise their price target for NVAX.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/695000724","repostId":"2200247876","repostType":2,"isVote":1,"tweetType":1,"viewCount":1165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}